Christopher E. Rudd

From Wikipedia, the free encyclopedia

Christopher Edward Rudd (born November 2, 1953) is a Canadian-born immunologist-biochemist. He is currently a Wellcome Trust Principal Fellow and a Professor of Molecular Immunolology at the University of Cambridge, as well as the Head of the Cell Signalling Section.[1]

Early life and education

Rudd was born in Toronto, Canada. He was educated at the Jesuit-run Brebeuf College School and at McGill University in Montreal. He received PhD and DSc degrees from University College, London. He held faculty positions at Harvard Medical School and Imperial College London before moving to Cambridge.

Research

Rudd is credited with having had a major impact on the understanding of the intracellular signals that control T-cell immunity. Rudd was the first[1] to discover that intracellular protein kinases interact with surface receptors, by identifying the interaction of T-cell co-receptors CD4 (also the receptor for the human immunodeficiency virus, HIV-1) and CD8 on T-cells with protein-tyrosine kinase p56lck. His discovery provided a role for members of the proto-oncogene pp60src kinase family in normal cell signaling. Subsequent to this, many other receptors were also then found to use src-related kinases to regulate cell growth. The CD4- and CD8-p56lck complexes are now widely accepted as the initiators of the T-cell activation cascade, leading to the recruitment and activation of a second tyrosine kinase ZAP-70, and which control the ability of T-cells to respond to foreign pathogens, allogeneic transplants and cancer cells.

In a second area, Rudd also elucidated signaling mechanisms by which co-receptors CD28 and CTLA-4 modulate T-cell responses. By showing that CTLA-4 activates T-cell motility and migration, he has proposed the 'reverse-stop signal model' to account for CTLA-4 down regulation of the responses of conventional T-cells to antigen. His research has also shown that a mutant form of an adapter protein termed ADAP can block the infection of T-cells by the Human Immunodeficiency Virus (HIV-1) by simultaneously interfering with HIV-1 replication and the transmission of the virus between T-cells.

Recognition

He has received awards including the Cancer Research Institute/Benjamin Jacobson Family Investigator Award (New York) and the Claudia Adams Barr Research Award (Boston). He has been a Scholar of the Leukemia Society of America and is now a Principal Research Fellow of the Wellcome Trust.

Publications

  • Rudd CE, Trevillyan JM, Wong LL, Dasgupta JD, Schlossman SF. (1998) The CD4 receptor is complexed to a T-cell specific tyrosine kinase (pp58) in detergent lysates from human T lymphocytes. Proc Nat'l Acad Sci USA. 85, 5190-94.
  • Barber, EK, Dasgutpa JD, Schlossman SF, Trevillyan JM, Rudd CE. (1989) The CD4 and CD8 antigens are coupled to a protein-tyrosine kinase (p56lck) that phosphorylates the CD3 complex. Proc. Nat'l. Acad. Sci. USA 86, 3277-81.
  • Rudd CE. CD4, CD8 and the TcR/CD3 Complex: a novel class of protein tyrosine kinase receptor (1990) Immunology Today, 11, 400-406
  • Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, G Garside P, Rudd CE. (2006) Reversal of the TCR stop signal by CTLA-4. Science. 313,1972-5.
  • Wei B, Han L, Abbink TEM, Elisabetta G, Lim D, Thaker R, Gao W, Wang J, Lever A, Jolly C, Wang H, Rudd CE (2013) Immune adaptor ADAP in T cells regulates HIV-1 transcription and cell-cell viral spread via different co-receptors. Retrovirol. 10 (1):101.

References

  1. ↑ 1.0 1.1 "Professor Christopher Rudd". University of Cambridge. Retrieved 11 January 2014. 

External links

Faculty page, University of Cambridge

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.